Brain-Eye Amyloid Memory (BEAM) Study – Validation of ocular measures as potential biomarkers for early detection of brain amyloid and neurodegeneration.
“Amyloid” is an abnormal protein found in the brains of people with Alzheimer’s disease. It can now be detected using a special type of brain scan that can show amyloid in the brain with a scanning technique called amyloid Positron Emission Tomography (PET). The study is also investigating whether an eye test that looks at the thickness of the retina (back of the eye) could be used to screen for presence of brain shrinkage in people with dementia.


  • Baycrest
  • Centre for Addiction and Mental Health
  • St. Michael’s Hospital
  • Sunnybrook Health Sciences Centre
  • University Health Network (UHN)
  • University of Toronto


  • Center for Probe Development and Commercialization
  • Kensington Eye Institute

Principal Investigator:
Dr. Sandra Black

Dr. Tiffany Chow, Dr. Sherif El Defrawy, Dr. Corinne Fischer, Dr. Morris Freedman, Dr. Barry Greenberg, Dr. Nathan Herrmann, Dr. Sylvain Houle, Dr. Christopher Hudson, Dr. Peter Kertes, Dr. Alexander Kiss, Dr. Sanjeev Kumar, Dr. Anthony E. Lang, Dr. Efrem Mandelcorn, Dr. Edward Margolin, Dr. Mario Masellis, Dr. William McIlroy, Dr. Ur Metser, Dr. Doug Munoz, Dr. Bruce Pollock, Dr. Tarek Rajji, Dr. Ekaterina Rogaeva, Dr. Stephen Strother, Dr. Don Stuss, Dr. Richard Swartz, Dr. David Tang-Wai, Dr. Carmela Tartaglia, Dr. John Valliant, Dr. Aristotle Voineskos, Dr. Victor Yang, Dr. Katherine Zukotynski

Click here for more information on the BEAM study.